- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 38/23 - Calcitonines
Détention brevets de la classe A61K 38/23
Brevets de cette classe: 155
Historique des publications depuis 10 ans
|
12
|
7
|
9
|
11
|
11
|
4
|
4
|
10
|
9
|
11
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| MannKind Corporation | 523 |
8 |
| Enteris Biopharma, Inc. | 24 |
5 |
| Keybioscience AG | 15 |
5 |
| Camurus AB | 146 |
4 |
| Mondobiotech Laboratories AG | 311 |
4 |
| Novartis AG | 10685 |
3 |
| The Governors of the University of Alberta | 879 |
3 |
| Regeneron Pharmaceuticals, Inc. | 4377 |
3 |
| SDG, Inc. | 31 |
3 |
| Tokyo Institute of Technology | 1365 |
3 |
| The Royal Institution for The Advancement of Learning / McGill University | 698 |
3 |
| Kindeva Drug Delivery L.P., Kindeva GP II LLC, a Delaware limited liability company | 216 |
3 |
| Nepsone ehf | 4 |
3 |
| Park Therapeutics, Inc. | 6 |
3 |
| The Regents of the University of California | 20195 |
2 |
| Massachusetts Institute of Technology | 10128 |
2 |
| The General Hospital Corporation | 4789 |
2 |
| Asahi Kasei Pharma Corporation | 130 |
2 |
| The Broad Institute, Inc. | 1858 |
2 |
| Fidia Farmaceutici S.p.A. | 654 |
2 |
| Autres propriétaires | 90 |